Proof of concept for poor inhibitor binding and efficient formation of covalent adducts of KRASG12C and ARS compounds

被引:22
|
作者
Khrenova, Maria G. [1 ,2 ]
Kulakova, Anna M. [1 ]
Nemukhin, Alexander, V [1 ,3 ]
机构
[1] Lomonosov Moscow State Univ, Dept Chem, Moscow 119991, Russia
[2] Russian Acad Sci, Res Ctr Biotechnol, Bach Inst Biochem, Moscow 119071, Russia
[3] Russian Acad Sci, Emanuel Inst Biochem Phys, Moscow 119334, Russia
基金
俄罗斯科学基金会;
关键词
FORCE-FIELD; CRYSTAL-STRUCTURE; ACTIVE-SITE; RAS; MOLECULES; SOLVATION; MUTANT; MECHANISM; ENERGIES; COMPLEX;
D O I
10.1039/d0ob00071j
中图分类号
O62 [有机化学];
学科分类号
070303 ; 081704 ;
摘要
The use of selective covalent inhibitors with low binding affinity and high reactivity with the target enzyme is a promising way to solve a long-standing problem of the "undruggable" RAS-like proteins. Specifically, compounds of the ARS family that prevent the activation of the GDP-bound G12C mutant of Kirsten RAS (KRAS) are in the focus of recent experimental research. We report the first computational characterization of the entire reaction mechanism of the covalent binding of ARS-853 to the KRAS(G12C)center dot GDP complex. The application of molecular dynamics, molecular docking and quantum mechanics/molecular mechanics approaches allowed us to model the inhibitor binding to the protein and the chemical reaction of ARS-853 with Cys12 in the enzyme binding site. We estimated a full set of kinetic constants and carried out numerical kinetic analysis of the process. Thus, we were able to compare directly the physicochemical parameters of the reaction obtained in silico and the macroscopic parameters observed in experimental studies. From our computational results, we explain the observed unusual dependence of the rate constant of covalent complex formation, k(obs), on the ARS concentration. The latter depends both on the non-covalent binding step with the equilibrium constant, Ki, and on the rate constant of covalent adduct formation, k(inact). The calculated ratio k(inact)/K-i = 213 M-1 s(-1) reproduces the corresponding experimental value of 250 +/- 30 M-1 s(-1) for the interaction of ARS-853 with KRAS(G12C). Electron density analysis in the reactive region demonstrates that covalent bond formation occurs efficiently according to the Michael addition mechanism, which assumes the activation of the CvC bond of ARS-853 by a water molecule and Lys16 in the binding site of KRAS(G12C). We also refine the k(inact) and K-i constants of the ARS-107 compound, which shares common features with ARS-853, and show that the decrease in the k(inact)/K-i ratio in the case of ARS-107 is explained by changes in both K-i and k(inact) constants.
引用
收藏
页码:3069 / 3081
页数:13
相关论文
共 25 条
  • [1] Chemical Proteomic Characterization of a Covalent KRASG12C Inhibitor
    Wijeratne, Aruna
    Xiao, Junpeng
    Reutter, Christopher
    Furness, Kelly W.
    Leon, Rebecca
    Zia-Ebrahimi, Mohammad
    Cavitt, Rachel N.
    Strelow, John M.
    Van Horn, Robert D.
    Peng, Sheng-Bin
    Barda, David A.
    Engler, Thomas A.
    Chalmers, Michael J.
    ACS MEDICINAL CHEMISTRY LETTERS, 2018, 9 (06): : 557 - 562
  • [2] Hindered Biaryl Bond Construction and Subsequent Diastereomeric Crystallization to Produce an Atropisomeric Covalent KRASG12C Inhibitor ARS-2102
    Yang, Xiaogen
    Li, Zhiwen
    Xu, Wenwen
    Zhu, Guanming
    Feng, Xiantong
    Zhang, Jun
    Zhao, Hongbin
    Chen, Yuyin
    Kong, Jianshe
    Mai, Wanping
    Li, Lian-Sheng
    Pippel, Daniel J.
    Ren, Pingda
    Deng, Xiaohu
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2023, 27 (01) : 206 - 216
  • [3] Discovery of AZD4625, a Covalent Allosteric Inhibitor of the MutantGTPase KRASG12C
    Kettle, Jason G.
    Bagal, Sharan K.
    Bickerton, Sue
    Bodnarchuk, Michael S.
    Boyd, Scott
    Breed, Jason
    Carbajo, Rodrigo J.
    Cassar, Doyle J.
    Chakraborty, Atanu
    Cosulich, Sabina
    Cumming, Iain
    Davies, Michael
    Davies, Nichola L.
    Eatherton, Andrew
    Evans, Laura
    Feron, Lyman
    Fillery, Shaun
    Gleave, Emma S.
    Goldberg, Frederick W.
    Hanson, Lyndsey
    Harlfinger, Stephanie
    Howard, Martin
    Howells, Rachel
    Jackson, Anne
    Kemmitt, Paul
    Lamont, Gillian
    Lamont, Scott
    Lewis, Hilary J.
    Liu, Libin
    Niedbala, Michael J.
    Phillips, Christopher
    Polanski, Radek
    Raubo, Piotr
    Robb, Graeme
    Robinson, David M.
    Ross, Sarah
    Sanders, Matthew G.
    Tonge, Michael
    Whiteley, Rebecca
    Wilkinson, Stephen
    Yang, Junsheng
    Zhang, Wenman
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (09) : 6940 - 6952
  • [4] Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors
    Lanman, Brian A.
    Allen, Jennifer R.
    Allen, John G.
    Amegadzie, Albert K.
    Ashton, Kate S.
    Booker, Shon K.
    Chen, Jian Jeffrey
    Chen, Ning
    Frohn, Michael J.
    Goodman, Guy
    Kopecky, David J.
    Liu, Longbin
    Lopez, Patricia
    Low, Jonathan D.
    Ma, Vu
    Minatti, Ana E.
    Nguyen, Thomas T.
    Nishimura, Nobuko
    Pickrell, Alexander J.
    Reed, Anthony B.
    Shin, Youngsook
    Siegmund, Aaron C.
    Tamayo, Nuria A.
    Tegley, Christopher M.
    Walton, Mary C.
    Wang, Hui-Ling
    Wurz, Ryan P.
    Xue, May
    Yang, Kevin C.
    Achanta, Pragathi
    Bartberger, Michael D.
    Canon, Jude
    Hollis, L. Steven
    McCarter, John D.
    Mohr, Christopher
    Rex, Karen
    Saiki, Anne Y.
    San Miguel, Tisha
    Volak, Laurie P.
    Wang, Kevin H.
    Whittington, Douglas A.
    Zech, Stephan G.
    Lipford, J. Russell
    Cee, Victor J.
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (01) : 52 - 65
  • [5] Covalent inhibitor targets KRasG12C: A new paradigm for drugging the undruggable and challenges ahead
    Li, Hui-yu
    Qi, Wei-liang
    Wang, Yu-xiang
    Meng, Ling-hua
    GENES & DISEASES, 2023, 10 (02) : 403 - 414
  • [6] Development of covalent KRASG12C inhibitor APG-1842 for the treatment of solid tumors
    Gu, Shaoulai
    Li, Qiang
    Li, Chao
    Wang, Qixin
    Fang, Douglas D.
    Wang, Shaomeng
    Yang, Dajun
    Zhai, Yifan
    CANCER RESEARCH, 2022, 82 (12)
  • [7] The discovery and preclinical characterization of the potent covalent KRASG12C inhibitor UCT-001024
    Rose, Tristin E.
    O'Boyle, Brendan M.
    Hilf, Justin A.
    Baker-Tripp, Emma L.
    Feng, Zhengao
    Yang, Kevin
    Bartberger, Michael D.
    Loson, Oliver C.
    O'Brien, Neil A.
    McDermott, Martina S.
    Kamranpour, Naeimeh
    Jia, Weiping
    Luo, Tong
    Ayala, Raul
    Glasby, John
    Stoltz, Brian M.
    Slamon, Dennis J.
    CANCER RESEARCH, 2023, 83 (07)
  • [8] Design, Structure Optimization, and Preclinical Characterization of JAB-21822, a Covalent Inhibitor of KRASG12C
    Li, Amin
    Li, Sujing
    Wang, Peng
    Dang, Chaojie
    Fan, Xinrui
    Chen, Mengran
    Liu, Dan
    Li, Fu
    Liu, Huan
    Zhang, Wei
    Wang, Yanping
    Wang, Yinxiang
    JOURNAL OF MEDICINAL CHEMISTRY, 2025, 68 (03) : 2422 - 2436
  • [9] Fit-for-Purpose Synthesis of a KRASG12C Covalent Inhibitor, via a Diastereoselective Hayashi Arylation
    Molinaro, Carmela
    Wong, Nicholas
    White, Nicholas A.
    Sirois, Lauren E.
    Bigler, Raphael
    Bindschaedler, Quentin P.
    Do, Steven
    Malhotra, Sushant
    Gosselin, Francis
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2024, 28 (08) : 3313 - 3325
  • [10] Synthesis of Adagrasib (MRTX849), a Covalent KRASG12C Inhibitor Drug for the Treatment of Cancer
    Chen, Cheng-yi
    Lu, Zhichao
    Scattolin, Thomas
    Chen, Chengsheng
    Gan, Yonghong
    McLaughlin, Mark
    ORGANIC LETTERS, 2023, : 944 - 949